ArticleFrontiers in pharmacology2025
Development of a warning model for drug-induced liver injury in the older patients.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liposomal Myricetin Nanoantioxidants Attenuate Methotrexate-Induced Hepatotoxicity by Modulating Oxidative Stress, Inflammation, and Apoptosis in Rats.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Drug-induced liver injury (DILI) is a significant adverse drug reaction, ranging from mild liver enzyme elevations to severe outcomes such as liver failure, transplantation, or death. This condition is especially concerning in older adults, who may exhibit increased susceptibility to adverse medication effects. This study aimed to develop and compare eight machine learning (ML) models using routine clinical, pharmacological, and laboratory data to predict DILI in older hospitalized patients. Methods: We conducted a retrospective analysis of older patients hospitalized in 2022 who exhibited abnormal liver function tests. A total of 421 clinical, pharmacological, and laboratory variables were utilized for model development, with missing data addressed through multiple imputation techniques. The performance of 8 ML algorithms-XGBoost, LightGBM, Random Forest, AdaBoost, CatBoost, Gradient Boosting Decision Trees, Artificial Neural Network, and TabNet-was assessed. The dataset was randomly partitioned into a training set (80%, n = 2,880) and an independent testing set (20%, n = 720). Model performance was evaluated using the area under the receiver operating characteristic curve (AUC). Results: Out of the 3,600 older patients with abnormal liver function, 654 patients experienced DILI. The best-performing model, LightGBM combined with Random Forest imputation, achieved an AUC of 0.9829. SHapley Additive exPlanations (SHAP) analysis identified critical predictors for DILI, including the timing of DILI relative to surgery, undergoing surgery, and maximum rate of change (slope) in liver enzymes, albumin, lipoprotein cholesterol, total bilirubin, proBNP, and total bile acids. Additional significant factors included administration of liver-protective medications upon admission; use of diuretics, antibiotics, and narcotic analgesics; and pre-existing liver or gallbladder diseases or malignancies. Discussion: The predictive model developed demonstrated excellent performance in identifying DILI in older adults. Leveraging machine learning techniques, this model holds significant potential for clinical implementation to effectively warn clinicians of DILI risk among older hospitalized patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.